Vanadium, ruthenium and copper compounds: a new class of nonplatinum metallodrugs with anticancer activity
I Esteban Leon… - Current medicinal …, 2017 - ingentaconnect.com
Cancer is a group of diseases involving abnormal cell growth. The cells grow uncontrollably
with the potential to invade and spread to other parts of the body. This disease is one of the …
with the potential to invade and spread to other parts of the body. This disease is one of the …
Construction of homo and heteronuclear Ru (II), Ir (III) and Re (I) complexes for target specific cancer therapy
More than 10 million death tolls in 2020 were reported as a result of heinous impact of
cancer, making it second most prime cause of death after cardiovascular diseases. In …
cancer, making it second most prime cause of death after cardiovascular diseases. In …
RuII(p-cymene) Compounds as Effective and Selective Anticancer Candidates with No Toxicity in Vivo
Ruthenium (II) complexes are currently considered a viable alternative to the widely used
platinum complexes as efficient anticancer agents. We herein present the synthesis and …
platinum complexes as efficient anticancer agents. We herein present the synthesis and …
A ruthenium-based 5-fluorouracil complex with enhanced cytotoxicity and apoptosis induction action in HCT116 cells
VR Silva, RS Corrêa, LS Santos, MBP Soares… - Scientific Reports, 2018 - nature.com
Combination of multifunctionalities into one compound is a rational strategy in medicinal
chemical design, and have often been used with metallodrug-based compounds. In the …
chemical design, and have often been used with metallodrug-based compounds. In the …
Recent advances in cytotoxicity, cellular uptake and mechanism of action of ruthenium metallodrugs: A review
Due to these limitations of platinum-based drugs, it has now become a challenge for
researchers to find out a potential scaffold furnished with indispensable properties like …
researchers to find out a potential scaffold furnished with indispensable properties like …
Synthesis, characterization, cellular uptake and apoptosis-inducing properties of two highly cytotoxic cyclometalated ruthenium (II) β-carboline complexes
Two new cyclometalated Ru (II) complexes of the general formula [Ru (NN) 2 (1-Ph-βC)](PF
6), where N–N= 4, 4′-dimethyl-2, 2′-bipyridine (dmb, Ru1), 2, 2′-bipyridine (bpy, Ru2) …
6), where N–N= 4, 4′-dimethyl-2, 2′-bipyridine (dmb, Ru1), 2, 2′-bipyridine (bpy, Ru2) …
GSH-resistant and highly cytoselective ruthenium (II)-p-cymene-(imidazo [4, 5-f][1, 10] phenanthrolin-2-yl) phenol complexes as potential anticancer agents
To avoid the side effects of the current popular platinum-based anticancer drugs,
researchers have made tireless attempts to design appropriate GSH-resistant Ru (II)-arene …
researchers have made tireless attempts to design appropriate GSH-resistant Ru (II)-arene …
[HTML][HTML] Ruthenium p-Cymene Complexes Incorporating Substituted Pyridine–Quinoline-Based Ligands: Synthesis, Characterization, and Cytotoxic Properties
A Kokkosi, E Garofallidou, N Zacharopoulos… - Molecules, 2024 - mdpi.com
Organometallic complexes of the formula [Ru (N^ N)(p-cymene) Cl][X](N^ N= bidentate
polypyridyl ligands, p-cymene= 1-methyl-4-(1-methylethyl)-benzene, X= counter anion), are …
polypyridyl ligands, p-cymene= 1-methyl-4-(1-methylethyl)-benzene, X= counter anion), are …
Why concurrent CDDP and radiotherapy has synergistic antitumor effects: a review of in vitro experimental and clinical-based studies
S Nagasawa, J Takahashi, G Suzuki, Y Hideya… - International journal of …, 2021 - mdpi.com
Chemo-radiotherapy, which combines chemotherapy with radiotherapy, has been clinically
practiced since the 1970s, and various anticancer drugs have been shown to have a …
practiced since the 1970s, and various anticancer drugs have been shown to have a …
CuAAC “Click”-Derived Luminescent 2-(2-(4-(4-(Pyridin-2-yl)-1H-1,2,3-triazol-1-yl)butoxy)phenyl)benzo[d]thiazole-Based Ru(II)/Ir(III)/Re(I) Complexes as Anticancer …
L Thilak Babu, P Paira - ACS omega, 2023 - ACS Publications
To enhance the cytoselective behavior of the complexes, we intended to develop a CuAAC
“click”-derived synthetic protocol for the preparation of 2-(2-(4-(4-(pyridin-2-yl)-1 H-1, 2, 3 …
“click”-derived synthetic protocol for the preparation of 2-(2-(4-(4-(pyridin-2-yl)-1 H-1, 2, 3 …